Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Plan ahead with key data on upcoming stock reports - all in 1 place
See Calendar
Close

Evaxion Biotech AS (EVAX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Evaxion Biotech AS's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.970 +0.250    +9.19%
16:43:47 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 179,145
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.850 - 3.090
Evaxion Biotech AS 2.970 +0.250 +9.19%

Evaxion Biotech AS Company Profile

 
Get an in-depth profile of Evaxion Biotech AS, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

46

Equity Type

DRC

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Contact Information

Address Dr. Neergaards Vej 5th Floor
Horsholm, 2970
Denmark
Phone 45 31 31 97 53
Fax -

Top Executives

Name Age Since Title
Marianne Sogaard 56 2020 Independent Chairwoman of the Board
Patrick Ott - - Member of Advisory Board
Christian Schilling - - Member of Advisory Board
Kirsten Aarup Drejer 68 2021 Member of Advisory Board
Georgina Long - - Member of Advisory Board
Anthony Purcell - - Member of Advisory Board
Lars Aage-Staal Wegner 50 2017 Director
Rajeev Surati - - Member of Advisory Board
Thomas Wylonis - - Member of Advisory Board
Roberto Prego Pineda 55 2018 Independent Director
Jeffrey S. Weber - - Member of Advisory Board
Robert J. Palay 68 - Member of Advisory Board
Jürgen Langhärig - 2019 Member of Advisory Board
Andrew C. Webber - - Member of Advisory Board
Soren Brunak - - Member of Advisory Board
Michael W. Washabaugh - - Member of Advisory Board
Lars Holtug 66 2021 Independent Director
Helen Tayton-Martin - 2025 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EVAX Comments

Write your thoughts about Evaxion Biotech AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email